

DRUG DISCOVERY TODAY**Editorial**

Editor: Steve Carney
Senior Editor: Ulrike Knies-Bamforth
Editorial Coordinator: Dan Huke
Illustrations: The Studio
Publishing Manager: Jaap van Harten
Editorial Enquiries:
Drug Discovery Today
 Elsevier
 84 Theobald's Road, London, UK WC1X 8RR
 Tel: +44 20 7611 4400
 Fax: +44 20 7611 4485
 Email: ddt@drugdiscoverytoday.com

ADVISORY EDITORIAL BOARD

Jeff Augen *TurboWorx, USA*
Jurgen Bajorath *University of Bonn, Germany*
Walter Blackstock *Experimental Therapeutics Centre, Singapore*
David Brayden *University College Dublin, Ireland*
Paul Caron *Vertex Pharmaceuticals, USA*
David Cavalla *Arachnova, UK*
David Clark *Argenta Discovery, UK*
Dalia Cohen *Rosetta Genomics, USA*
Christine DeBouck *GlaxoSmithKline, USA*
Sean Ekins *ACT LLC and Collaborations in Chemistry, USA*
Hans-Peter Fischer *GeneData, Switzerland*
Kevin Fitzgerald *Bristol Myers-Squibb, USA*
Peter Ghazal *University of Edinburgh, UK*
Christopher M. Hill *Organon, UK*
Nick Hird *Takeda Chemical Industries, Japan*
Enoch Huang *Pfizer, USA*
Thomas Joos *University of Tuebingen, Germany*
Vincent H.L. Lee *Chinese University of Hong Kong, Hong Kong*
David Lewin *Yale University, USA*
Christopher A. Lipinski *Melior Discovery, USA*
Lorenz Mayr *Novartis, Switzerland*
Nick Meanwell *Bristol-Myers Squibb, USA*
Mark Murcko *Vertex Pharmaceuticals, USA*
Fajun Nan *Shanghai Institute of Materia Medica, China*
Stephen Naylor *Predictive Physiology and Medicine Inc., USA*
Eric Neumann *Teranode, USA*
Tim Peakman *UK Biobank, UK*
Norton Peet *Aurigene, USA*
Manuel Peitsch *Novartis, Switzerland*
Kurt Rasmussen *Eli Lilly and Co. Ltd. USA*
Janice Reichert *Tufts Center for the Study of Drug Development, USA*
John Reidhaar-Olson *Hoffmann-La Roche, USA*
Mike Romanos *GlaxoSmithKline, UK*
Raymond C. Rowe *Intelligensys, UK*
Andreas Russ *University of Oxford, UK*
Tomi Sawyer *ARIAD Pharmaceuticals, USA*
Esther Schmid *Pfizer, UK*
Jonathan Sheldon *Inforsense, UK*
Michael Snyder *Yale University, USA*
Nigel Spurr *GlaxoSmithKline, UK*
Susie Stephens *Eli Lilly and Co. Ltd., USA*
Robert Strausberg *The J. Craig Venter Institute, USA*
Donny Strosberg *Scripps Florida, USA*
Yuichi Sugiyama *University of Tokyo, Japan*
David Szymkowski *Xencor, USA*
Nick Terrett *Ensemble Discovery, USA*
Vladimir Torchilin *Northeastern University, Boston, USA*
Mark Whittaker *Evotec OAI, UK*
Hans Winkler *Johnson and Johnson, Belgium*
Limsoon Wong *Laboratories for Information Technology (LIT), Singapore*
X.F. Steven Zheng *Robert Wood Johnson Medical School, USA*

DRUG DISCOVERY TODAY

PERSPECTIVE

INTERVIEW

789 Steve Carney talks to Mark Ashton and Mark Whittaker about Evotec and their approach to fragment-based drug discovery

Steve Carney

890 DIARY

FORTHCOMING ARTICLES:

Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective

by John R Desjarlais, Greg A. Lazar, Eugene A. Zhukovsky and Seung Y. Chu

The impact of pharmacogenetics on the development and use of antipsychotic drugs

by Gavin P. Reynolds

MCH-R1 Antagonists: What is keeping most research programs away from the clinic?

by José L. Méndez-Andino and John A. Vos

Combined therapy for tuberculosis and HIV-1: the challenge for drug discovery

by Dominique J. Pepper, Graeme J Meintjes, Helen McIlleron and Robert J. Wilkinson